Does Gabapentin Cause Weight Loss? Evidence Review (FDA Label, Real Direction)

The honest answer: no — gabapentin typically causes modest weight GAIN, not weight loss. Gabapentin (brand name Neurontin) is FDA-approved as adjunctive therapy for partial seizures and for postherpetic neuralgia. Its FDA label lists weight gain as a treatment-emergent adverse reaction at 2% (vs 0% placebo) in the postherpetic-neuralgia trials, and the DeToledo 1997 Ther Drug Monit epilepsy cohort^[1] on chronic high-dose gabapentin found a mean gain of about 5 lb (~2.2 kg) at 12 months — with roughly 57% of patients gaining more than 5% of baseline body weight. A subset of patients DO lose modest weight, usually driven by gabapentin-related sedation, dizziness, or nausea suppressing appetite — but the population-level signal across 25+ years of trial and post-marketing data is weight gain, not loss. Gabapentin is not a weight-loss drug. Below: the verbatim FDA label, the DeToledo 1997 epilepsy data, the GABA + voltage-gated calcium channel α2δ mechanism, the edema confounder, drug interactions, and how gabapentin compares to other AEDs and GLP-1s on weight.

At a glance — Gabapentin and weight

• Gabapentin is FDA-approved for adjunctive treatment of partial seizures and for postherpetic neuralgia — not for weight loss. Off-label uses include restless legs syndrome, anxiety, fibromyalgia, and alcohol-use disorder, but no FDA indication is weight-related.
• The FDA label flags weight gain, not weight loss. Table 3 of the postherpetic-neuralgia controlled trials lists weight gain at 2% on gabapentin vs 0% on placebo and peripheral edema at 8% vs 2%. Weight loss is not on the ≥1% adverse-reactions table for either indication.
• DeToledo 1997: ~5 lb mean gain at 12 months. The foundational clinical paper^[1] in adult epilepsy patients on chronic high-dose gabapentin (mean ~3,500 mg/day) found a mean gain of about 2.2 kg (~5 lb) at 12 months, with ~57% of patients gaining more than 5% of baseline body weight and ~10% gaining more than 10%.
• Class-review consensus. The Jallon 2001 Drug Safety review^[2] and Ben-Menachem 2007 Epilepsia review^[3] both classify gabapentin as a weight-positive antiepileptic alongside valproate, carbamazepine, and pregabalin — with topiramate, zonisamide, and felbamate as the weight-negative AEDs and lamotrigine and levetiracetam as weight-neutral.
• Mechanism. Despite its name, gabapentin does NOT bind GABA receptors. It is a structural GABA analog that binds the α2δ (alpha-2-delta) subunit of voltage-gated calcium channels, reducing excitatory neurotransmitter release in over-excited circuits. The appetite and weight signal is thought to be driven by hypothalamic effects + sedation + fluid retention rather than a direct metabolic effect.
• Edema is a confounder. Peripheral edema appears in 8% of postherpetic-neuralgia patients vs 2% on placebo. Some of the “weight gain” signal is interstitial fluid, not adipose tissue — particularly in the first 8–12 weeks.
• A subset of patients lose weight. Sedation, dizziness (~17% vs 5% in postherpetic neuralgia trials), somnolence (~21% vs 5%), and nausea can suppress appetite, particularly during dose titration. This minority experience drives the patient-forum weight-loss anecdotes — but they do not change the population-level direction.
• If weight is the goal, gabapentin is not the tool. For obesity itself, GLP-1 receptor agonists deliver 15–21% TBWL (Wegovy −14.9% in STEP-1^[6]; Zepbound −20.9% in SURMOUNT-1^[7]) — magnitudes no anticonvulsant approaches.

What gabapentin is

Gabapentin is the generic name for the gamma-aminobutyric acid analog originally marketed as Neurontin by Parke-Davis (now Pfizer) starting in 1993. It is widely available as 100, 300, and 400 mg capsules; 600 and 800 mg tablets; and a 250 mg/5 mL oral solution. Extended-release formulations (Gralise, Horizant) are also marketed.

Gabapentin’s mechanism is frequently misunderstood. Despite being a structural analog of GABA (gamma-aminobutyric acid), it does not bind GABA-A or GABA-B receptors, does not affect GABA reuptake, and is not metabolized to GABA. The principal mechanism is high-affinity binding to the α2δ subunit of voltage-gated calcium channels — particularly Ca_V2.1 and Ca_V2.2 channels in the central nervous system. This binding reduces calcium influx at pre-synaptic terminals, which in turn reduces release of excitatory neurotransmitters (glutamate, substance P, norepinephrine) in over-excited circuits. Pregabalin (Lyrica) shares this mechanism with higher binding affinity.

Gabapentin has:

• No GABA-A activity. It is not a benzodiazepine, not a barbiturate, and does not directly enhance GABA-A chloride conductance. The sedation profile is mechanistically different from those classes (and from phenobarbital).
• No sodium-channel blockade. Unlike phenytoin, carbamazepine, lamotrigine, and oxcarbazepine, gabapentin does not block voltage-gated sodium channels at therapeutic concentrations.
• Predominantly renal elimination. Gabapentin is not metabolized by the liver to any clinically significant degree and is excreted unchanged in urine. Dose adjustment is required for impaired renal function (CrCl < 60 mL/min).

Typical dosing for partial seizures starts at 300 mg three times daily and titrates to 1,800–3,600 mg/day. Postherpetic- neuralgia dosing starts at 300 mg day 1, 600 mg day 2, 900 mg day 3, then titrates to 1,800 mg/day in three divided doses (up to 3,600 mg/day). Restless-legs and anxiety off-label use is usually lower (600–1,800 mg/day).

What the FDA label actually says about weight

From the gabapentin package insert (DailyMed, Teva Pharma- ceuticals), the directly weight- and intake-relevant statements:

Indications, Postherpetic Neuralgia: “Gabapentin capsules are indicated for the management of postherpetic neuralgia in adults.”

Indications, Epilepsy: “Gabapentin capsules are indicated as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in adults and pediatric patients 3 years and older with epilepsy.”

Adverse Reactions, Table 3 (postherpetic neuralgia, ≥1% and more frequent than placebo): Weight gain — gabapentin 2%, placebo 0%. Peripheral edema — gabapentin 8%, placebo 2%. Somnolence ~21% vs ~5%. Dizziness ~17% vs ~5%. Ataxia ~3% vs 0%.

Warnings, Anaphylaxis and Angioedema: “Gabapentin can cause anaphylaxis and angioedema after the first dose or at any time during treatment.”

Warnings, Suicidal Behavior and Ideation: pooled AED class analysis — incidence of suicidal thoughts or behavior 0.43% on AEDs vs 0.24% on placebo.

Warnings, Respiratory Depression: 2019 FDA safety communication — concomitant opioid or benzodiazepine use, COPD, and other causes of respiratory compromise increase risk of serious breathing problems.

The label’s asymmetry is decisive. Weight gain appears in the ≥1% adverse-reactions table; weight loss does not. Peripheral edema appears at 8% vs 2% — a four-fold elevation that explains some of the early-treatment weight signal as fluid retention rather than adipose accumulation. In FDA-label nomenclature, the absence of weight loss from the ≥1% table combined with the presence of weight gain is the textbook signature of a weight-positive drug, not a weight-neutral or weight-negative one.

Gabapentin’s FDA label carries no boxed warning. The principal labeled risks are anaphylaxis/angioedema, suicidal behavior/ideation (AED class), respiratory depression (2019 update), DRESS, and abrupt- discontinuation seizures.

Where to verify: the gabapentin package insert lives on DailyMed at SetID c7f21eaa-68ee-420c-9c98-e997cc73a297 (Teva Pharmaceuticals re-label). Use DailyMed, not accessdata.fda.gov — the latter 404s silently when label revisions ship.

The DeToledo 1997 epilepsy cohort: the foundational data point

The DeToledo 1997 Ther Drug Monit paper^[1] remains the most-cited clinical reference for gabapentin’s weight-gain signal. The study followed 44 adult patients with refractory epilepsy on chronic high-dose gabapentin therapy (mean dose ~3,500 mg/day, range 1,800–4,800 mg/day) over 12 months:

• Mean weight gain ~2.2 kg (~5 lb) at 12 months across the full cohort.
• ~57% of patients gained more than 5% of their baseline body weight.
• ~10% gained more than 10% of baseline body weight — the clinically significant subgroup.
• The gain occurred early (most evident in the first 3 months) and tended to plateau by 6–9 months — a pattern consistent across subsequent AED weight-effect literature.
• Higher gabapentin doses were associated with larger gains, suggesting a dose-response relationship rather than a purely idiosyncratic effect.

The DeToledo paper’s ~5 lb mean is the single most- repeated number in clinical references on gabapentin and weight. It is not a head-to-head with placebo, but the broader AED literature reviewed by Jallon 2001^[2] and Ben-Menachem 2007^[3] consistently classifies gabapentin in the weight-positive AED tier. Domecq 2015^[5] — the canonical reference for drugs commonly associated with weight change — includes gabapentin in the antiepileptic-class summary of weight- positive medications. Ness-Abramof 2005^[4] classed gabapentin among drug-induced weight gain agents in the anticonvulsant subgroup.

Why gabapentin causes weight gain (mechanism)

The mechanism is incompletely understood, but four contributing pathways have been proposed in the literature:

• Hypothalamic appetite signaling. Animal studies suggest gabapentinoids modulate neuropeptide Y and orexin signaling in hypothalamic appetite circuits, with the net effect being increased appetite, particularly for carbohydrate-dense foods. Patient-reported “sweet cravings” on gabapentin are common.
• Sedation-driven reduced activity. Somnolence (~21% vs ~5% in postherpetic-neuralgia trials), dizziness (~17%), and ataxia (~3%) reduce non-exercise activity thermogenesis (NEAT) and incidental movement — the same indirect mechanism that drives the modest weight gain seen with chronic benzodiazepines and some antipsychotics.
• Peripheral edema (fluid retention). Peripheral edema appears in 8% of postherpetic-neuralgia patients (vs 2% on placebo). Mechanism: gabapentinoid effects on capillary endothelial calcium channels increase fluid movement into interstitial space. This is not adipose-tissue weight gain — but it shows up on the scale identically and contributes substantially to the early-treatment signal (first 8–12 weeks).
• Improved sleep / pain control as a confounder. For postherpetic-neuralgia or restless-legs patients whose chronic pain or sleep disruption had suppressed appetite, effective treatment may simply allow appetite to return to a population-typical baseline. This is not a direct pharmacological weight effect — but the patient still experiences it as “gabapentin made me gain weight.”

Notably, gabapentin does NOT engage the H1 histamine, M1 muscarinic, or 5-HT2C serotonergic receptor systems that drive the substantial weight gain seen with mirtazapine, paroxetine, and the atypical antipsychotics. Its weight signal is meaningfully smaller than those classes — ~5 lb mean rather than 5–15+ lb — but consistently directional.

Off-label uses and weight

Gabapentin is heavily off-label prescribed, and the indication matters somewhat for weight risk:

• Restless legs syndrome (RLS). Gabapentin enacarbil (Horizant) is FDA-approved for moderate-to-severe primary RLS; immediate-release gabapentin is widely used off-label. Doses are typically lower (600–1,800 mg/day) than for epilepsy. Weight signal is present but smaller at these doses.
• Anxiety disorders (generalized anxiety, social anxiety). Gabapentin is used off-label as an SSRI/ benzodiazepine alternative, particularly in patients with substance-use-disorder concerns. Doses ~900–1,800 mg/day. The weight-gain signal still applies; for weight- concerned anxiety patients, buspirone is typically more weight-favorable. See our review of buspirone and weight.
• Fibromyalgia. Pregabalin (Lyrica) is FDA- approved for fibromyalgia; gabapentin is used off-label. Both gabapentinoids carry the weight-gain signal — pregabalin’s FDA label flags weight gain at ~4– 16% across pivotal trials depending on dose and indication.
• Alcohol-use disorder. Multiple RCTs (Mason, Anton, others) have shown gabapentin reduces heavy-drinking days in alcohol-use disorder. Weight effects in this population are confounded by reduction in alcohol calories (potentially producing weight LOSS as drinking decreases) and improvement in baseline nutritional status (potentially producing weight GAIN as appetite normalizes). Net direction is variable.
• Diabetic peripheral neuropathy. Gabapentin is used off-label; pregabalin and duloxetine are first-line FDA-approved options. Weight signal is present.
• Hot flashes / vasomotor symptoms. Gabapentin 300–900 mg/day is used off-label as a non-hormonal vasomotor symptom treatment. Same weight signal, attenuated at lower doses.

Peripheral edema as a weight confounder

The 8% peripheral edema rate (vs 2% placebo) in the postherpetic-neuralgia trials is clinically important and often underappreciated. Mechanism: gabapentinoid binding to the α2δ subunit on peripheral vascular smooth- muscle calcium channels increases capillary permeability and promotes fluid movement into interstitial spaces. The result is:

• Pitting edema in the ankles and feet — the most common presentation, particularly in elderly patients and patients with baseline heart failure, chronic kidney disease, or venous insufficiency.
• Weight gain that appears in the first 4–8 weeks on treatment — sometimes 2–4 kg (4–9 lb) of fluid weight that develops faster than adipose accumulation would.
• Worse in combination with calcium-channel blockers (amlodipine in particular). Dual-mechanism calcium-channel modulation amplifies the edema risk.
• Reversible. Edema usually resolves within 1–4 weeks of gabapentin discontinuation — the fluid signal disappears, leaving any true adipose gain behind.

For a patient who has gained 5–7 lb in the first 8 weeks on gabapentin, distinguishing fluid retention from adipose gain matters clinically. Bilateral pitting ankle edema, rapid onset (within weeks), and reversibility on discontinuation favor fluid. Gradual onset over 3–6 months without edema favors true weight gain.

Why a subset of patients lose weight on gabapentin

Patient forums include genuine reports of modest weight loss on gabapentin. These are real and are not inconsistent with a population-level weight-positive signal. The mechanisms:

• Titration-related sedation and dizziness. Somnolence (~21% vs 5% placebo), dizziness (~17% vs 5%), and ataxia (~3% vs 0%) are most prominent during the first 1–4 weeks of titration. They can suppress appetite and reduce meal frequency — some patients lose 1–3 kg over the first 4–8 weeks before tolerance develops and the underlying weight-positive signal asserts itself.
• Nausea. Less common than sedation but present in some patients during titration; transient and usually does not produce sustained weight loss.
• Alcohol-use disorder population. Patients taking gabapentin for alcohol-use disorder may lose weight as they reduce alcohol calories — this is mediated by the alcohol reduction, not by gabapentin’s direct pharmacology.
• Improved sleep / reduced pain leading to increased activity. For postherpetic-neuralgia or fibromyalgia patients whose chronic pain limited activity, effective analgesia may increase movement and produce modest weight loss — offsetting some of the appetite-driven gain.
• Reverse causation in the chronic-pain population. Some patients had been overeating to cope with chronic pain; effective gabapentin treatment removes the trigger.

These mechanisms explain the patient-forum anecdotes but do not change the population-level direction. The DeToledo 1997 cohort^[1] and the broader AED literature consistently show net weight GAIN at the cohort level.

Gabapentin vs other AEDs vs GLP-1s on weight

Antiepileptic drugs split cleanly into three weight-effect tiers, useful framing for a patient choosing between options (within the constraint of what is clinically appropriate for their indication):

• Weight-positive AEDs: gabapentin, pregabalin (Lyrica), valproate (Depakote), carbamazepine (Tegretol), vigabatrin. The Jallon 2001 Drug Saf review^[2] identified this class with valproate as the strongest signal (~5–10 kg over 1 year). Gabapentin and pregabalin are intermediate (~2–5 kg). Carbamazepine is modest (~1–3 kg).
• Weight-negative AEDs: topiramate (Topamax, a component of Qsymia for obesity), zonisamide (Zonegran), felbamate (Felbatol). Topiramate is in Phentermine/Topiramate (Qsymia) precisely because of its weight-loss signal at 200–400 mg/day. See our overview of non-GLP-1 drug weight effects.
• Weight-neutral AEDs: lamotrigine (Lamictal), levetiracetam (Keppra), oxcarbazepine (Trileptal), phenytoin (Dilantin). These are the typical preferred options when weight is a meaningful clinical concern and the indication allows substitution.

For epilepsy patients on chronic gabapentin where weight has become an issue, the conversation with the prescribing neurologist often centers on whether seizure control is adequate, whether substitution to lamotrigine or levetiracetam is clinically feasible, and whether the gabapentin dose can be reduced. For postherpetic-neuralgia patients, duloxetine (Cymbalta) and tricyclic antidepressants are alternatives, though both also carry weight signals (duloxetine modestly weight-positive at 12+ months; TCAs substantially weight- positive).

Magnitude: gabapentin vs other AEDs vs GLP-1s on weight

Cross-trial caveat: figures above are from independent trials and cohorts with different populations, designs, and durations. They cannot be used to predict individual outcomes, and they are not head-to-head comparisons. The gabapentin row reflects the DeToledo 1997 mean; AED comparator values are approximate meta-analytic anchors from Jallon 2001 and Ben-Menachem 2007; GLP-1 rows are the STEP-1 and SURMOUNT-1 primary endpoints.

Drug-interaction watchpoints

Gabapentin is not metabolized by CYP enzymes and does not inhibit or induce them — so the CYP-mediated interactions that dominate most psychotropic and AED labels are absent here. The clinically meaningful interactions are:

• Opioids (respiratory depression). The 2019 FDA safety communication specifically flags concomitant opioid + gabapentinoid use as a respiratory-depression risk. Patients on chronic opioid therapy who add gabapentin should be monitored for sedation, slow breathing, and oxygen desaturation — particularly in the elderly, in COPD, and during dose escalation.
• Benzodiazepines and other CNS depressants. Additive sedation. Alcohol, hypnotics, sedating antihistamines, and tramadol all amplify gabapentin’s somnolence and dizziness.
• Antacids (aluminum/magnesium hydroxide). Reduce gabapentin bioavailability by ~20%. Separate dosing by 2 hours.
• Morphine. Increases gabapentin AUC by ~44% via altered gastrointestinal motility. May require dose adjustment if both are co-prescribed.
• Calcium-channel blockers (amlodipine). Amplifies peripheral-edema risk. Consider this in patients with hypertension or angina on chronic CCB therapy who add gabapentin.
• GLP-1 receptor agonists. No pharmacokinetic interaction. GLP-1s are peptides cleared peptide-style, not via CYP enzymes; gabapentin is cleared renally without hepatic metabolism. Overlapping early nausea is the principal practical issue during simultaneous GLP-1 dose escalation. The directional effects oppose: GLP-1s drive weight loss; gabapentin adds modest weight-positive pressure. Net direction in a patient on both is typically still weight loss, but smaller than GLP-1 monotherapy would produce.

What to do if you gain weight on gabapentin

Weight gain on chronic gabapentin is common enough that it deserves a structured clinical approach rather than unilateral discontinuation:

• Document timing and rate. Edema-driven gain appears in the first 4–8 weeks, often with pitting ankle swelling. Adipose-driven gain develops more gradually over 3–12 months without overt edema. The two have different reversibility profiles — edema resolves within 1–4 weeks of discontinuation; adipose changes require active weight management.
• Rule out the easy confounders. Concurrent new medications (especially mirtazapine, paroxetine, atypical antipsychotics, glucocorticoids, calcium-channel blockers), reduced activity from the underlying condition, new alcohol use, and dietary changes all dwarf gabapentin’s direct effect.
• Talk to the prescribing clinician about alternatives. For epilepsy: lamotrigine, levetiracetam, oxcarbazepine are weight-favorable substitutes when seizure type and patient history allow. For postherpetic neuralgia: duloxetine, lidocaine 5% patch, capsaicin 8% patch, tricyclic antidepressants. For restless legs syndrome: rotigotine, pramipexole, ropinirole. For anxiety: buspirone (weight-neutral), SSRIs (variable; fluoxetine and sertraline more favorable than paroxetine).
• Consider dose reduction. The DeToledo cohort^[1] documented a dose-response relationship. If the indication allows a lower dose (e.g., postherpetic neuralgia at 1,800 mg/day instead of 3,600 mg/day), this can attenuate the weight effect without losing efficacy.
• If weight loss is the primary goal. Gabapentin is not the obstacle to remove. GLP-1 receptor agonists (semaglutide, tirzepatide), bupropion / naltrexone (Contrave), phentermine / topiramate (Qsymia), and (where appropriate) bariatric procedures are the evidence-based weight-loss interventions and can be added alongside continued gabapentin therapy if needed.
• Never stop gabapentin abruptly. Abrupt discontinuation in epilepsy patients can precipitate seizures — the FDA label warns explicitly. Taper over ≥1 week, longer for higher doses. Even in non- epilepsy patients on long-term gabapentin, a 1–2 week taper reduces the risk of rebound anxiety, insomnia, and (rarely) gabapentin-withdrawal seizures.

When to talk to a clinician

Reasons to bring up gabapentin weight changes with the prescribing clinician:

• >5% baseline weight gain in < 6 months — meaningful gain that warrants evaluating alternative AEDs/neuropathic-pain options.
• New bilateral ankle/leg edema — rule out congestive heart failure, renal insufficiency, venous thromboembolism; if isolated to gabapentin-related peripheral edema, consider dose reduction or substitution.
• Shortness of breath or new dyspnea on exertion — particularly in elderly patients or those with cardiac history; rule out heart failure with edema.
• Persistent somnolence/sedation — can indicate excessive dosing, drug-drug interaction (particularly with opioids/benzos), or impaired renal clearance.
• Concurrent suicidal thoughts or worsening mood — the AED-class suicidality warning applies; urgent clinical evaluation.
• Plan to start a weight-loss drug (GLP-1, Contrave, Qsymia) — not a contraindication, but worth flagging so the clinician can monitor for overlapping early-treatment nausea and adjust titration schedules.

Common bad takes

“Gabapentin causes weight loss.” No. The FDA label flags weight gain (2% vs 0% placebo) and peripheral edema (8% vs 2%) but does not flag weight loss on the ≥1% adverse-reactions table. The DeToledo 1997 epilepsy cohort^[1] documented a mean ~5 lb gain at 12 months. Class reviews^[2][3] classify gabapentin as a weight-positive AED.

“Gabapentin is a GABA drug, so it works like a benzo.” Mechanistically wrong. Despite the name, gabapentin does NOT bind GABA-A or GABA-B receptors. It binds the α2δ subunit of voltage-gated calcium channels. It is not a benzodiazepine, not a barbiturate, and does not directly enhance GABA-ergic neurotransmission.

“The weight gain on gabapentin is mostly water, so it doesn’t count.” Partially true, partially not. Peripheral edema accounts for some of the early-treatment signal (the 8% vs 2% rate explains 2– 4 kg of fluid retention in some patients). But the DeToledo cohort followed patients out to 12 months, by which point edema has typically equilibrated and the residual ~5 lb mean gain is largely adipose. The signal is real, even if part of it is fluid.

“Topiramate and gabapentin are basically the same thing.” No. They are both AEDs but have fundamentally different mechanisms (gabapentin: α2δ binding; topiramate: sodium-channel blockade, GABA-A enhancement, AMPA/kainate antagonism, carbonic anhydrase inhibition) and opposite weight signals. Topiramate is weight-negative (and a component of Qsymia for obesity at 200–400 mg/day). Gabapentin is weight-positive.

“Gabapentin will help with weight loss because it sedates me and I eat less.” Possible in the first 1–4 weeks during titration, but unreliable as a weight-loss strategy. Sedation-driven appetite suppression is transient (tolerance develops in weeks), and the underlying weight-positive signal asserts itself by month 3–6. Using gabapentin specifically for weight loss is not evidence-based.

“Gabapentin is safer than benzodiazepines so the weight gain doesn’t matter.” Gabapentin has a more favorable abuse-liability and respiratory-depression profile than benzodiazepines, but the 2019 FDA respiratory- depression warning narrowed the gap, particularly with concurrent opioid use. Weight gain is a legitimate adverse effect to discuss with the prescribing clinician.

Bottom line

• Gabapentin is FDA-approved for postherpetic neuralgia and as adjunctive therapy for partial seizures — not for weight loss.
• Gabapentin typically causes weight gain, not loss. The FDA label lists weight gain at 2% vs 0% placebo and peripheral edema at 8% vs 2% in postherpetic- neuralgia trials. Weight loss does not appear on the ≥1% adverse-reactions table.
• Magnitude: ~5 lb (~2.2 kg) mean gain at 12 months per the DeToledo 1997 Ther Drug Monit cohort^[1]; ~57% of patients gain >5% of baseline weight. Class reviews^[2][3] classify gabapentin as a weight-positive AED.
• Mechanism includes hypothalamic appetite effects, sedation-driven reduced activity, and peripheral edema. Gabapentin binds the α2δ subunit of voltage-gated calcium channels — despite the name, it does NOT bind GABA receptors.
• Some patients lose weight from titration- related sedation/dizziness/nausea or from reduced alcohol intake (in alcohol-use-disorder use) — but these mechanisms do not change the population-level direction.
• If weight gain becomes clinically significant, talk to the prescribing clinician. Lamotrigine and levetiracetam are weight-neutral AED alternatives for many epilepsy patients. Duloxetine and the 5% lidocaine patch are weight-favorable postherpetic-neuralgia alternatives. Never stop gabapentin abruptly — taper over ≥1 week to avoid rebound seizures.
• Do not use gabapentin for weight loss. If weight loss is the clinical goal, GLP-1 receptor agonists deliver 15–21% TBWL^[6][7] — magnitudes no AED approaches.

Related research

• Does Buspirone Cause Weight Loss? Honest Evidence Review
• Does Anxiety Cause Weight Loss? Mechanism, GI Symptoms, Sleep
• Does Paxil cause weight loss? Honest evidence review
• GLP-1 side-effect questions answered
• Non-GLP-1 drug weight-effect lookup tool

Important disclaimer. This article is educational and does not constitute medical advice. Gabapentin is FDA-approved as adjunctive therapy for partial seizures and for postherpetic neuralgia; it is not FDA- approved for weight loss or obesity. Decisions about starting, stopping, switching, or dose-adjusting anticonvulsants or neuropathic-pain medications should be made with a qualified prescribing clinician. Abrupt discontinuation in epilepsy patients can precipitate seizures — always taper under clinical supervision. The 2019 FDA respiratory-depression warning applies particularly to patients on concurrent opioids, benzodiazepines, or with COPD.